BI-1808

고객리뷰

Based on 1 Customer Validation

BI-1808 is a fully human IgG1 monoclonal antibody targeting human tumor necrosis factor receptor 2 (TNFR2) (KD = 646 pM). BI-1808 inhibits Treg survival by blocking the interaction between TNFR2 and its ligand TNF-α, and via its IgG1 Fc segment binds FcγR to target and deplete intratumoral Tregs (ADCC/ADCP) and induce pro-inflammatory reprogramming of myeloid cells, ultimately activating CD8+ effector T cell-mediated tumor rejection. BI-1808 can produce synergistic antitumor effects with Pembrolizumab (HY-P9902). BI-1808 can be used for research in tumor immunity.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity : 97.75%
  • 분자량:144.206 kDa
  • 보관:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Biological Activity
  • Chemical Information
  • Protocol
  • 순도&문서
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00